206 related articles for article (PubMed ID: 9814459)
1. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender.
Indridason OS; Pieper CF; Quarles LD
J Clin Endocrinol Metab; 1998 Nov; 83(11):3860-6. PubMed ID: 9814459
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
[TBL] [Abstract][Full Text] [Related]
5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
6. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
7. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
Alghareeb A; Sabry A; Bawadekji H; Alsaran K
Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
9. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
10. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
11. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease.
Lippuner K; Zehnder HJ; Casez JP; Takkinen R; Descoeudres C; Jaeger P
Nephrol Dial Transplant; 1996 Jan; 11(1):70-4. PubMed ID: 8649655
[TBL] [Abstract][Full Text] [Related]
12. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
15. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
16. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA
Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
[TBL] [Abstract][Full Text] [Related]
17. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
19. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
20. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
